BioSpace News Archive

Know Labs, Inc., an emerging developer of non-invasive medical diagnostic technology, announced the appointment of three new members to the Company’s Board of Directors.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update.

Stratus® Medical, a company focused on improving clinical outcomes for chronic pain patients by advancing radiofrequency (RF) technology for the treatment of pain, announced today the issuance of its fifth U.S. patent (U.S. Patent No. 11,806,070) and first two Canadian patents (Canadian Patent Nos. 2,778,997 and 2,799,505) for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode (“NIMBUS”).

The global rapid microbiology testing market size is expected to surpass around USD 12.37 billion by 2032 from USD 5.2 billion in 2022 and it is anticipated to grow at a CAGR of 9.1% between 2023 to 2032.

Alkermes is committed to operating in a manner that protects our employees, our environment and our communities.

Candidate is 10x more sensitive to target peptide than competitor candidates

The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity.

Castle Biosciences, Inc. announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this month: Stephens Annual Investment Conference on Nov. 15, 2023, at 11:00 a.m. Eastern Time.